1
|
Humphries TLR, Shen K, Iyer A, Johnson DW, Gobe GC, Nikolic-Paterson D, Fairlie DP, Vesey DA. PAR2-Induced Tissue Factor Synthesis by Primary Cultures of Human Kidney Tubular Epithelial Cells Is Modified by Glucose Availability. Int J Mol Sci 2021; 22:ijms22147532. [PMID: 34299151 PMCID: PMC8304776 DOI: 10.3390/ijms22147532] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Revised: 07/07/2021] [Accepted: 07/07/2021] [Indexed: 01/05/2023] Open
Abstract
Coagulopathies common to patients with diabetes and chronic kidney disease (CKD) are not fully understood. Fibrin deposits in the kidney suggest the local presence of clotting factors including tissue factor (TF). In this study, we investigated the effect of glucose availability on the synthesis of TF by cultured human kidney tubular epithelial cells (HTECs) in response to activation of protease-activated receptor 2 (PAR2). PAR2 activation by peptide 2f-LIGRLO-NH2 (2F, 2 µM) enhanced the synthesis and secretion of active TF (~45 kDa) which was blocked by a PAR2 antagonist (I-191). Treatment with 2F also significantly increased the consumption of glucose from the cell medium and lactate secretion. Culturing HTECs in 25 mM glucose enhanced TF synthesis and secretion over 5 mM glucose, while addition of 5 mM 2-deoxyglucose (2DOG) significantly decreased TF synthesis and reduced its molecular weight (~40 kDa). Blocking glycosylation with tunicamycin also reduced 2F-induced TF synthesis while reducing its molecular weight (~36 kDa). In conclusion, PAR2-induced TF synthesis in HTECs is enhanced by culture in high concentrations of glucose and suppressed by inhibiting either PAR2 activation (I-191), glycolysis (2DOG) or glycosylation (tunicamycin). These results may help explain how elevated concentrations of glucose promote clotting abnormities in diabetic kidney disease. The application of PAR2 antagonists to treat CKD should be investigated further.
Collapse
Affiliation(s)
- Tyrone L. R. Humphries
- Centre for Kidney Disease Research, Translational Research Institute, Faulty of Medicine, The University of Queensland at the Princess Alexandra, Brisbane, QLD 4072, Australia; (T.L.R.H.); (K.S.); (D.W.J.); (G.C.G.)
| | - Kunyu Shen
- Centre for Kidney Disease Research, Translational Research Institute, Faulty of Medicine, The University of Queensland at the Princess Alexandra, Brisbane, QLD 4072, Australia; (T.L.R.H.); (K.S.); (D.W.J.); (G.C.G.)
| | - Abishek Iyer
- Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia; (A.I.); (D.P.F.)
- Centre for Inflammation and Disease Research, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - David W. Johnson
- Centre for Kidney Disease Research, Translational Research Institute, Faulty of Medicine, The University of Queensland at the Princess Alexandra, Brisbane, QLD 4072, Australia; (T.L.R.H.); (K.S.); (D.W.J.); (G.C.G.)
- Department of Nephrology, The University of Queensland at Princess Alexandra Hospital, Brisbane, QLD 4102, Australia
| | - Glenda C. Gobe
- Centre for Kidney Disease Research, Translational Research Institute, Faulty of Medicine, The University of Queensland at the Princess Alexandra, Brisbane, QLD 4072, Australia; (T.L.R.H.); (K.S.); (D.W.J.); (G.C.G.)
- School of Biomedical Sciences, Faculty of Medicine, The University of Queensland at the Translational Research Institute, Brisbane, QLD 4072, Australia
| | - David Nikolic-Paterson
- Department of Nephrology, Monash Medical Centre and Monash University Centre for Inflammatory Diseases, Melbourne, VIC 3168, Australia;
| | - David P. Fairlie
- Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia; (A.I.); (D.P.F.)
- Centre for Inflammation and Disease Research, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - David A. Vesey
- Centre for Kidney Disease Research, Translational Research Institute, Faulty of Medicine, The University of Queensland at the Princess Alexandra, Brisbane, QLD 4072, Australia; (T.L.R.H.); (K.S.); (D.W.J.); (G.C.G.)
- Department of Nephrology, The University of Queensland at Princess Alexandra Hospital, Brisbane, QLD 4102, Australia
- Correspondence: ; Tel.: +61-7-3443-8013
| |
Collapse
|
2
|
Lee MJ, Kim P. Recombinant Protein Expression System in Corynebacterium glutamicum and Its Application. Front Microbiol 2018; 9:2523. [PMID: 30416490 PMCID: PMC6213972 DOI: 10.3389/fmicb.2018.02523] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Accepted: 10/03/2018] [Indexed: 01/01/2023] Open
Abstract
Corynebacterium glutamicum, a soil-derived gram-positive actinobacterium, has been widely used for the production of biochemical molecules such as amino acids (i.e., L-glutamate and L-lysine), nucleic acids, alcohols, and organic acids. The metabolism of the bacterium has been engineered to increase the production of the target biochemical molecule, which requires a cytosolic enzyme expression. As recent demand for new proteinaceous biologics (such as antibodies, growth factors, and hormones) increase, C. glutamicum is attracting industrial interest as a recombinant protein expression host for therapeutic protein production due to the advantages such as low protease activity without endotoxin activity. In this review, we have summarized the recent studies on the heterologous expression of the recombinant protein in C. glutamicum for metabolic engineering, expansion of substrate availability, and recombinant protein secretion. We have also outlined the advances in genetic components such as promoters, surface anchoring systems, and secretory signal sequences in C. glutamicum for effective recombinant protein expression.
Collapse
Affiliation(s)
| | - Pil Kim
- Department of Biotechnology, The Catholirc University of Korea, Bucheon, South Korea
| |
Collapse
|
3
|
Wu YY, V. Nguyen A, Wu XX, Loh M, Vu M, Zou Y, Liu Q, Guo P, Wang Y, Montgomery LL, Orlofsky A, Rand JH, Lin EY. Antiphospholipid Antibodies Promote Tissue Factor–Dependent Angiogenic Switch and Tumor Progression. THE AMERICAN JOURNAL OF PATHOLOGY 2014; 184:3359-75. [DOI: 10.1016/j.ajpath.2014.07.027] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Revised: 07/22/2014] [Accepted: 07/29/2014] [Indexed: 12/30/2022]
|
4
|
Morizumi S, Hiramatsu Y, Matsuzaki K, Goto Y, Sato S, Abe M, Kato H, Matsubara M, Sakakibara Y. Early Heparin Administration Attenuates Tissue Factor-Mediated Thrombin Generation During Simulated Cardiopulmonary Bypass. J Card Surg 2013; 29:35-40. [DOI: 10.1111/jocs.12254] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Sei Morizumi
- Department of Cardiovascular Surgery; Faculty of Medicine; University of Tsukuba; Tsukuba Japan
| | - Yuji Hiramatsu
- Department of Cardiovascular Surgery; Faculty of Medicine; University of Tsukuba; Tsukuba Japan
| | - Kanji Matsuzaki
- Department of Cardiovascular Surgery; Faculty of Medicine; University of Tsukuba; Tsukuba Japan
| | - Yukinobu Goto
- Department of Cardiovascular Surgery; Faculty of Medicine; University of Tsukuba; Tsukuba Japan
| | - Shoko Sato
- Department of Cardiovascular Surgery; Faculty of Medicine; University of Tsukuba; Tsukuba Japan
| | - Masakazu Abe
- Department of Cardiovascular Surgery; Faculty of Medicine; University of Tsukuba; Tsukuba Japan
| | - Hideyuki Kato
- Department of Cardiovascular Surgery; Faculty of Medicine; University of Tsukuba; Tsukuba Japan
| | - Muneaki Matsubara
- Department of Cardiovascular Surgery; Faculty of Medicine; University of Tsukuba; Tsukuba Japan
| | - Yuzuru Sakakibara
- Department of Cardiovascular Surgery; Faculty of Medicine; University of Tsukuba; Tsukuba Japan
| |
Collapse
|
5
|
Recent advances in recombinant protein expression by Corynebacterium, Brevibacterium, and Streptomyces: from transcription and translation regulation to secretion pathway selection. Appl Microbiol Biotechnol 2013; 97:9597-608. [PMID: 24068337 DOI: 10.1007/s00253-013-5250-x] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2013] [Revised: 09/03/2013] [Accepted: 09/05/2013] [Indexed: 12/14/2022]
Abstract
Gram-positive bacteria are widely used to produce recombinant proteins, amino acids, organic acids, higher alcohols, and polymers. Many proteins have been expressed in Gram-positive hosts such as Corynebacterium, Brevibacterium, and Streptomyces. The favorable and advantageous characteristics (e.g., high secretion capacity and efficient production of metabolic products) of these species have increased the biotechnological applications of bacteria. However, owing to multiplicity from genes encoding the proteins and expression hosts, the expression of recombinant proteins is limited in Gram-positive bacteria. Because there is a very recent review about protein expression in Bacillus subtilis, here we summarize recent strategies for efficient expression of recombinant proteins in the other three typical Gram-positive bacteria (Corynebacterium, Brevibacterium, and Streptomyces) and discuss future prospects. We hope that this review will contribute to the development of recombinant protein expression in Corynebacterium, Brevibacterium, and Streptomyces.
Collapse
|